{"commentary":{"count":31,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":12,"podcast":8,"x_thread":8,"x_video":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT01777152\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"ECHELON-2","nct_id":"NCT01777152","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=echelon-2-nct01777152. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"ECHELON-2","arms":[{"description":"cyclophosphamide, doxorubicin, vincristine, and prednisone","label":"CHOP","type":"ACTIVE_COMPARATOR"},{"description":"brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone","label":"A+CHP","type":"EXPERIMENTAL"}],"collaborators":["Millennium Pharmaceuticals, Inc."],"completion_date":{"date":"2020-10-02","type":"ACTUAL"},"conditions":["Anaplastic Large-Cell Lymphoma","Non-Hodgkin Lymphoma","T-Cell Lymphoma"],"enrollment":{"count":452,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"brentuximab vedotin","type":"DRUG"},{"name":"doxorubicin","type":"DRUG"},{"name":"prednisone","type":"DRUG"},{"name":"vincristine","type":"DRUG"},{"name":"cyclophosphamide","type":"DRUG"}],"last_update":"2021-11-30","lead_sponsor":"Seagen Inc.","official_title":"A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2018-08-15","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free Survival Per Independent Review Facility (IRF)","timeFrame":"Up to 60 months"}],"references":[{"citation":"Iyer S, Mehta-Shah N, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Alpdogan O, Feldman TA, Camus V, Gritti G, Zinzani PL, Belada D, Mayer J, Choi I, Cheong JW, Rustia E, Fenton K, Fanale M, Savage KJ, Horwitz SM. Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma. Blood Adv. 2025 Dec 9;9(23):5976-5987. doi: 10.1182/bloodadvances.2024015282.","pmid":"40829107","type":"DERIVED"},{"citation":"Domingo-Domenech E, Pro B, Illidge T, Horwitz S, Trumper L, Iyer S, Advani R, Bartlett NL, Christensen JH, Kim WS, Feldman T, Choi I, Gritti G, Belada D, Shustov A, Illes A, Zinzani PL, Huttmann A, Trneny M, Le Gouill S, Jagadeesh D, Friedberg JW, Little M, Dong C, Fanale M, Fenton K, Savage KJ. Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up. Blood Cancer J. 2025 Aug 1;15(1):129. doi: 10.1038/s41408-025-01329-2.","pmid":"40750774","type":"DERIVED"},{"citation":"Savage KJ, Horwitz SM, Advani R, Christensen JH, Domingo-Domenech E, Rossi G, Morschhauser F, Alpdogan O, Suh C, Tobinai K, Shustov A, Trneny M, Yuen S, Zinzani PL, Trumper L, Ilidge T, O'Connor OA, Pro B, Miao H, Bunn V, Fenton K, Fanale M, Puhlmann M, Iyer S. Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2. Blood Adv. 2022 Oct 11;6(19):5550-5555. doi: 10.1182/bloodadvances.2020003971.","pmid":"35470385","type":"DERIVED"},{"citation":"Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illes A, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Huttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trumper L; ECHELON-2 Study Group. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4.","pmid":"30522922","type":"DERIVED"},{"citation":"Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Huebner D, Kennedy DA, Shustov AR. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. J Clin Oncol. 2014 Oct 1;32(28):3137-43. doi: 10.1200/JCO.2013.54.2456. Epub 2014 Aug 18.","pmid":"25135998","type":"DERIVED"}],"start_date":{"date":"2013-01-31","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas","url":"https://clinicaltrials.gov/study/NCT01777152"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/echelon-2-nct01777152"}